Preeclampsia (PE) poses serious risks to pregnant women and newborns, and low molecular weight heparins (LMWHs) are explored for their potential therapeutic benefits.
LMWHs demonstrated a reduction in blood pressure, proteinuria, and trophoblast cell apoptosis in rat models of PE, suggesting they may alleviate symptoms of the condition.
The study also uncovered that LMWHs activate the PI3K/AKT signaling pathway, providing a molecular mechanism for their protective effects against PE.